This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Y. Search for Related Content PubMed PubMed Citation Articles by Wang, Y. Related Collections Contractile function Cardiovascular Pharmacology Cell signalling/signal transduction Gene regulation Genetically altered mice Heart failure - basic studies Physiological and pathological control of gene expression

(Circulation. 2007;116:1413-1423.)
© 2007 American Heart Association, Inc.

Basic Science for Clinicians

Mitogen-Activated Protein Kinases in Heart Development and Diseases

Yibin Wang, PhD

From the Departments of Anesthesiology, Physiology, and Medicine, David Geffen School of Medicine, Molecular Biology Institute, University of California at Los Angeles, Los Angeles.

Correspondence to Dr Yibin Wang, Professor, Departments of Anesthesiology, Medicine, and Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095. E-mail yibinwang{at}mednet.ucla.edu

Mitogen-activated protein (MAP) kinases belong to a highly conserved family of Ser-Thr protein kinases in the human kinome and have diverse roles in broad physiological functions. The 4 best-characterized MAP kinase pathways, ERK1/2, JNK, p38, and ERK5, have been implicated in different aspects of cardiac regulation, from development to pathological remodeling. Recent advancements in the development of kinase-specific inhibitors and genetically engineered animal models have revealed significant new insights about MAP kinase pathways in the heart. However, this explosive body of new information also has yielded many controversies about the functional role of specific MAP kinases as either detrimental promoters or critical protectors of the heart during cardiac pathological processes. These uncertainties have raised questions on whether/how MAP kinases can be targeted to develop effective therapies against heart diseases. In this review, recent studies examining the role of MAP kinase subfamilies in cardiac development, hypertrophy, and survival are summarized.

Key Words: heart failure • molecular biology • signal transduction

This article has been cited by other articles:

				E. Bartha, I. Solti, L. Kereskai, J. Lantos, E. Plozer, K. Magyar, E. Szabados, T. Kalai, K. Hideg, R. Halmosi, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats Cardiovasc Res, August 1, 2009; 83(3): 501 - 510. [Abstract] [Full Text] [PDF]

				A. Skoura and T. Hla Regulation of vascular physiology and pathology by the S1P2 receptor subtype Cardiovasc Res, May 1, 2009; 82(2): 221 - 228. [Abstract] [Full Text] [PDF]

				W. Liu, M. Zi, J. Jin, S. Prehar, D. Oceandy, T. E. Kimura, M. Lei, L. Neyses, A. H. Weston, E. J. Cartwright, et al. Cardiac-Specific Deletion of Mkk4 Reveals Its Role in Pathological Hypertrophic Remodeling but Not in Physiological Cardiac Growth Circ. Res., April 10, 2009; 104(7): 905 - 914. [Abstract] [Full Text] [PDF]

				N. Koleganova, G. Piecha, E. Ritz, and M.-L. Gross Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats Nephrol. Dial. Transplant., March 1, 2009; 24(3): 778 - 787. [Abstract] [Full Text] [PDF]

				P. J. H. Smeets, H. M. de Vogel-van den Bosch, P. H. M. Willemsen, A. P. Stassen, T. Ayoubi, G. J. van der Vusse, and M. van Bilsen Transcriptomic analysis of PPAR{alpha}-dependent alterations during cardiac hypertrophy Physiol Genomics, December 12, 2008; 36(1): 15 - 23. [Abstract] [Full Text] [PDF]

				K. Gong, Z. Li, M. Xu, J. Du, Z. Lv, and Y. Zhang A Novel Protein Kinase A-independent, {beta}-Arrestin-1-dependent Signaling Pathway for p38 Mitogen-activated Protein Kinase Activation by {beta}2-Adrenergic Receptors J. Biol. Chem., October 24, 2008; 283(43): 29028 - 29036. [Abstract] [Full Text] [PDF]

				I. Szokodi, R. Kerkela, A.-M. Kubin, B. Sarman, S. Pikkarainen, A. Konyi, I. G. Horvath, L. Papp, M. Toth, R. Skoumal, et al. Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac Contractility Circulation, October 14, 2008; 118(16): 1651 - 1658. [Abstract] [Full Text] [PDF]

				L. Bertrand, S. Horman, C. Beauloye, and J.-L. Vanoverschelde Insulin signalling in the heart Cardiovasc Res, July 15, 2008; 79(2): 238 - 248. [Abstract] [Full Text] [PDF]

				K. Venkatachalam, S. Mummidi, D. M. Cortez, S. D. Prabhu, A. J. Valente, and B. Chandrasekar Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2078 - H2087. [Abstract] [Full Text] [PDF]

				C. LaCroix, J. Freeling, A. Giles, J. Wess, and Y.-F. Li Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H810 - H820. [Abstract] [Full Text] [PDF]